Start of production in record time: Evonik delivers first lipids from German facility to BioNTech today
Availability of COVID-19 vaccine to increase significantly
pixabay.com
"Setting up production at this speed is a great achievement," says Christian Kullmann, chairman of Evonik's executive board. "Increasing lipid production in Germany will also allow us to further accelerate the manufacturing of larger quantities of the vaccine. In this way, we are contributing to the fight against the pandemic."
As part of its strategic partnership with BioNTech, Evonik produces two different lipids for the Pfizer-BioNTech COVID-19 vaccine. Together with other lipids, they encapsulate to form a lipid nanoparticle (LNP), which serves as a protective shell around the mRNA to transport it safely into the cell. There, the mRNA is released to allow the vaccine to take effect.
"This is a complex production process that only a few in the world master," says Dr. Thomas Riermeier, head of Evonik's Health Care business line. "We're demonstrating once more that Evonik is a superior and reliable partner for the pharmaceutical industry, far beyond COVID-19."
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.